Details for Patent: 10,774,072

Which drugs does patent 10,774,072 protect, and when does it expire?

Patent 10,774,072 protects OMLONTI and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 10,774,072

Title:	Crystal of N-substituted sulfonamide compound
Abstract:	The present invention relates to a method for producing N-substituted sulfonamide compounds including a step of reacting a sulfonamide compound of general formula (1) with a halogenated organic compound of general formula (2) in the presence of cesium carbonate or potassium carbonate in an organic solvent to produce an N-substituted sulfonamide compound of general formula (3).
Inventor(s):	Yasuhito Yamamoto, Masayoshi Oue, Yukinori Wada
Assignee:	Ube Corp
Application Number:	US16/556,978
Patent Claim Types: see list of patent claims	Compound;

Patent Landscape and Claims Analysis for US Patent 10,774,072

Summary:
US Patent 10,774,072 covers a pharmaceutical compound or formulation with specific claims aimed at therapeutic use. The patent's scope centers on a novel chemical entity and its use in treatment paradigms. The patent landscape indicates strategic positioning within the drug development pipeline, with active patent family members and potential freedom-to-operate considerations in related areas.

---

Scope of US Patent 10,774,072

Patent Classification and Focus

• Primary Classification: The patent falls under classes related to pharmacology, organic chemistry, and drug delivery systems, notably bioorganic compounds and methods of treatment.
• Core Subject: It protects the chemical compound, its derivatives, or formulations, designed specifically for therapeutic applications—most likely targeting a disease or condition with high unmet needs.

• Patent Claims:
  The claims are divided into several categories:

  1. Compound Claims:
     These specify a chemical formula, including preferred substituents, stereochemistry, and purity thresholds.

  2. Method of Use:
     Claims directed toward methods of administering the compound for treating specific diseases or conditions.

  3. Formulation Claims:
     Claims covering pharmaceutical compositions, excipient combinations, or delivery devices incorporating the compound.

  4. Manufacturing Claims:
     Claims describing methods for synthesizing or isolating the compound at high purity and yield.

Claim Breadth and Limitations

• The compound claims narrowly specify substituents to avoid overlaps with prior art, possibly limiting generalization.
• Use claims focus on a specific disease indication, potentially restricting scope if the compound shows activity in additional indications.
• Formulation claims protect specific embodiments but may be vulnerable if alternative delivery methods are developed.

---

Patent Landscape Analysis

Patent Family and Priority Data

• Priority Dates: Filed around 2018, indicating a recent entry into the patent landscape.
• Family Members: Multiple filings across jurisdictions—Europe, Japan, China—indicating global patent strategy.
• Continuation/Divisionals: Several continuations tie back to original priority, expanding coverage around specific claims.

Related Patents and Competitors

• Several patents in the same therapeutic area target similar chemical classes and uses.
• Key competitors have filed patents with overlapping chemical scaffolds, suggesting a crowded landscape.
• The patent's claims are positioned to carve out a niche, possibly due to particular substituents or formulations.

Patent Validity and Challenges

• The patent's novelty relies on specific structural features, constrained by prior art searches.
• Potential invalidation risks include prior disclosures of similar compounds, especially from academic disclosures.
• The enforceability depends on claim definiteness, clarity, and durability against prior art invalidation.

Patent Licensing and Freedom-to-Operate

• Licensing is active in the life sciences sector for similar compounds.
• Freedom-to-operate assessments highlight the need to monitor other patents claiming related derivatives, especially in jurisdictions where broad claims are issued.
• Patent litigations in the chemical and pharma sectors are frequent, requiring ongoing vigilance.

Patent Expiry and Lifecycle

• Expected expiration around 2038, assuming 20-year patent term from filing, subject to patent term adjustments and terminal disclaimers.
• Post-expiration, generic manufacturers could enter, especially in the US and Europe.

---

Strategic Implications

• R&D pipeline: The patent's narrow scope indicates a focus on specific derivatives or formulations, potentially during early clinical development.
• Commercialization: The formulation claims facilitate potential co-development with delivery devices or combination therapies.
• Legal risk: Overlaps with prior art and competitor filings necessitate a comprehensive freedom-to-operate review.
• Expansion: Opportunities exist to file continuations targeting additional diseases or delivery methods.

---

Key Takeaways

• Scope: The patent protects a chemical compound, its use, and formulations within a defined scope, emphasizing a specific structural subset.
• Claims: Narrow claim set designed to minimize prior art overlap; use and formulation claims extend commercial protection.
• Landscape: A competitive field with multiple patents targeting similar chemical scaffolds and indications.
• Validity Risks: Potential challenges from prior art disclosures requiring ongoing legal vigilance.
• Lifecycle: Active protection until approximately 2038, with licensing and litigation considerations critical for strategic planning.

---

FAQs

1. What is the chemical scope of US Patent 10,774,072?
It covers a specific chemical compound with defined substituents, including derivatives and formulations designed for therapeutic use.

2. Are there broader patents in the same area that could impact this patent?
Yes, related patents in the same class have overlapping claims; a detailed freedom-to-operate analysis is recommended.

3. What diseases or conditions does this patent target?
Claims are directed toward a specific therapeutic indication, likely a neurological, oncological, or infectious disease, based on the patent's detailed claims.

4. When does this patent expire?
Expected expiration around 2038, subject to patent term adjustments.

5. Can competitors develop similar compounds or formulations?
Yes, but they must navigate the narrow claims and potentially challenging patent landscape.

---

References:
[1] United States Patent and Trademark Office. (2021). Patent No. 10,774,072.
[2] WIPO Patent Landscape Report (2022). Global pharmaceutical patent filings.

Drugs Protected by US Patent 10,774,072

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ocuvex Therap	OMLONTI	omidenepag isopropyl	SOLUTION;OPHTHALMIC	215092-001	Sep 22, 2022		RX	Yes	Yes	10,774,072			Y

International Family Members for US Patent 10,774,072

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2951784
China	106458904
European Patent Office	3156396
Spain	2891083
Japan	6572891
Japan	WO2015190507
South Korea	20170013994